Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis

BACKGROUND: Research on JAK family members as therapeutic targets for autoimmune diseases has brought tofacitinib and baricitinib into clinical for the treatment of rheumatoid arthritis and other autoimmune diseases. Despite the potent efficacy of these first-generation JAK inhibitors, their broad-s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Inflamm Res
Autors principals: Zhang, Ning, Zhang, Changqing, Zeng, Zhihong, Zhang, Jiyong, Du, Shengnan, Bao, Chunde, Wang, Zhe
Format: Artigo
Idioma:Inglês
Publicat: Dove 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8153205/
https://ncbi.nlm.nih.gov/pubmed/34054304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JIR.S301076
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars